Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2007; 28(6): 672-677
DOI: 10.1055/s-2007-996414
DOI: 10.1055/s-2007-996414
Optimizing Therapy for Stenotrophomonas maltophilia
Further Information
Publication History
Publication Date:
20 December 2007 (online)
ABSTRACT
Stenotrophomonas (Xanthomonas) maltophilia is a nonfermentative, gram-negative bacillus that is widely distributed in natural and humanmade environments. In the nonhospital setting it is an uncommon pathogen, typically causing soft tissue infection of contaminated wounds. In the hospital setting, particularly among critical care and oncology patients, S. maltophilia may cause catheter-related bacteremia, pneumonia, soft tissue infection, meningitis, prosthetic valve endocarditis, and ocular infections. S. maltophilia is usually resistant to multiple antimicrobials, including expanded-spectrum penicillins, third-generation cephalosporins, carbapenems, aminoglycosides, and quinolones. Trimethoprim-sulfamethoxazole is the antimicrobial agent of choice for this pathogen but is bacteriostatic. Further, resistance to this agent is increasing. Certain combinations of antibiotics are synergistic and may be appropriate for patients harboring resistant organisms or with life-threatening infections.
KEYWORDS
Stenotrophomonas (Xanthomonas) maltophilia - nosocomial infections - antimicrobial resistance
REFERENCES
- 1 Denton M, Kerr K G. Microbiologic and clinical aspects of infection associated with Stenotrophomonas maltophilia. . Clin Microbiol Rev. 1998; 11 57-80
- 2 Agger W A, Cogbill T H, Busch H, Landercasper J, Callister S M. Wounds caused by corn-harvesting machines: an unusual source of infection due to gram-negative bacilli. Rev Infect Dis. 1986; 8 927-931
- 3 Daley A J, McIntyre P B. Stenotrophomonas maltophilia and lawn mower injuries in children. J Trauma. 2000; 48 536-539
- 4 Heath T, Currie B. Nosocomial and community-acquired Xanthomonas maltophilia infection in tropical Australia. J Hosp Infect. 1995; 30 309-313
- 5 Elting L S, Bodey G P. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter related infections. Medicine. 1990; 69 296-306
- 6 Khardori N, Elting L, Wong E, Schable B, Bodey G P. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis. 1990; 12 997-1003
- 7 Muder R R, Harris A P, Muller S et al.. Bacteremia due to Stenotrophomonas maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996; 22 508-512
- 8 Lai C-H, Chi C-Y, Chen H-P et al.. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect. 2004; 37 350-358
- 9 Wang W-S, Liu C-P, Lee C-M, Huang F-Y. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect. 2004; 37 359-365
- 10 Vartivarian S E, Papadakis K A, Palacios J A, Manning J T, Anaissie E J. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia: a new spectrum. Ann Intern Med. 1994; 121 969-973
- 11 Papadakis K A, Varivarian S E, Vassilaki M E, Anaissie E J. Stenotrophomonas maltophilia meningitis: report of two cases and review of the literature. J Neurosurg. 1997; 87 106-108
- 12 Mehta N J, Khan I A, Mehta R N, Gulati A. Stenotrophomonas maltophilia endocarditis of prosthetic aortic valve: report of a case and review of literature. Heart Lung. 2000; 29 351-355
- 13 Penland R L, Wilhelmus K R. Stenotrophomonas maltophilia ocular infections. Arch Ophthalmol. 1996; 114 433-436
- 14 McGowen J E. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med. 2006; 119 S29-S36
- 15 Weber D J, Rutala W A, Blanchet C N, Jordan M, Gergen M F. Faucet aerators: a source of patient colonization with Stenotrophomonas maltophilia . Am J Infect Control. 1999; 27 59-63
- 16 Verweij P E, Meis J F, Christmann V et al.. Nosocomial outbreak of colonization and infection with Stenotrophomonas maltophilia in preterm infants associated with contaminated tap water. Epidemiol Infect. 1998; 120 251-256
- 17 Denton M, Rajgopal A, Mooney L et al.. Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis. J Hosp Infect. 2003; 55 180-183
- 18 Lanotte P, Cantagrel S, Mereghetti L et al.. Spread of Stenotrophomonas maltophilia colonization in a pediatric intensive care unit detected by monitoring tracheal bacterial carriage and molecular typing. Clin Microbiol Infect. 2003; 9 1142-1147
- 19 Marshall W F, Keating M R, Anhalt J P, Steckelberg J M. Xanthomonas maltophilia: an emerging nosocomial pathogen. Mayo Clin Proc. 1989; 64 1097-1104
- 20 Victor M A, Arpi M, Bruun B, Jonsson V, Hansen M M. Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis. 1994; 26 163-170
- 21 Tsai W P, Chen C L, Ko W C, Pan S C. Stenotrophomonas maltophilia bacteremia in burn patients. Burns. 2006; 32 155-158
- 22 Figueiredo P M, Furumura M T, Santos A M et al.. Cytotoxic activity of Stenotrophomonas maltophilia . Lett Appl Microbiol. 2006; 43 443-449
- 23 Waters V J, Gomz M I, Soong G, Amin S, Ernst R K, Prince A. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia . Infect Immun. 2007; 75 1698-1703
- 24 Micozzi A, Venditti M, Monaco M et al.. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis. 2000; 31 705-711
- 25 Sattler C A, Mason E O, Kaplan S L. Nonrespiratory Stenotrophomonas maltophilia infection at a children's hospital. Clin Infect Dis. 2000; 31 1321-1330
- 26 Boktour M, Hanna H, Ansari S et al.. Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer. 2006; 106 1967-1973
- 27 Wu P S, Lu C Y, Chang L Y et al.. Stenotrophomonas maltophilia bacteremia in pediatric patients: a 10 year analysis. J Microbiol Immunol Infect. 2006; 39 144-149
- 28 Pathmanathan A, Waterer A. Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. Eur Respir J. 2005; 25 911-914
- 29 Elsner H A, Duhrsen U, Hollwitz B, Kaulfers P M, Hossfeld D K. Fatal pulmonary hemorrhage in patients with acute leukemia and fulminant pneumonia caused by Stenotrophomonas maltophilia . Ann Hematol. 1997; 74 155-161
- 30 Burns J L, Emerson J, Stapp J R et al.. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis. 1998; 27 158-163
- 31 Marchac V, Equil A, Le Behan-Benjamin C, Hodson M, Bush A. Case control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J. 2004; 23 98-102
- 32 Downhour N P, Petersen E A, Krueger T S, Tangella K V, Nix D E. Severe cellulitis/myositis caused by Stenotrophomonas maltophilia . Ann Pharmacother. 2002; 36 63-66
- 33 Aydin K, Koksol I, Kaygusuz S, Kaklikkaya I, Caylan R, Ozdemir R. Endocarditis caused by Stenotrophomonas maltophilia . Scand J Infect Dis. 2000; 32 427-430
- 34 Gutierrez Rodero F, del Mar Masia M, Cortes J, Ortiz de la Tabla V, Mainar V, Vilar A. Endocarditis caused by Stenotrophomonas maltophilia: case report and review. Clin Infect Dis. 1996; 23 1261-1265
- 35 Al-Hilali N, Nampoory M R, Johny K V, Chugh T D. Xanthomonas maltophilia infection in chronic peritoneal dialysis. Scand J Urol Nephrol. 2000; 34 67-69
- 36 Szeto C C, Li P K, Leung C B, Yu A W, Lui S F, Lai K N. Xanthomonas maltophilia peritonitis in uremic patients receiving continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1997; 29 91-95
- 37 Saino Y, Kobayashi M, Inoue M, Mitsuhashi S. Purification and properties of inducible penicillin β-lactamase isolated from Pseudomonas maltophilia . Antimicrob Agents Chemother. 1982; 22 564-570
- 38 Saino Y, Inoue M, Mitsuhashi S. Purification of an inducible cephalosporinase from Pseudomonas maltophilia GN12873. Antimicrob Agents Chemother. 1984; 25 362-365
- 39 Avison M B, von Heldreich C J, Higgins C S, Bennett P M, Walsh T RA. TEM-2 β-lactamase encoded on an active TN1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia . J Antimicrob Chemother. 2000; 46 879-884
- 40 al Naiemi N, Duim B, Bart A A. CTX-M extended-spectrum beta-lactamase in Pseudomonas aeruginosa and Stenotrophomonas maltophilia . J Med Microbiol. 2006; 55 1607-1608
- 41 Chang L L, Chen H F, Chang C Y, Lee T M, Wu W J. Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia . J Antimicrob Chemother. 2004; 53 518-521
- 42 Pankuch G A, Jacobs M R, Rittenhouse S F, Appelbaum P C. Susceptibilities of 123 strains of Xanthomonas maltophilia to eight β-lactams (including β-lactam-β-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrob Agents Chemother. 1994; 38 2317-2322
- 43 Fass R J, Barnishan J, Solomon M C, Ayers L W. In vitro activities of quinolones, β-lactams, tobramycin, and trimethoprim-sulfamethoxazole against non-fermentative gram-negative bacilli. Antimicrob Agents Chemother. 1996; 40 1412-1418
- 44 Valdezate S, Vindel A, Loza E, Baquero F, Canton R. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemother. 2001; 45 1581-1584
- 45 Betriu C, Sanchez A, Palau M L, Gomez M, Picazo J J. Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999. J Antimicrob Chemother. 2001; 48 152-154
- 46 Gales A C, Jones R N, Foward K R, Linares J, Sader H S, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiologic features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis. 2001; 32(Suppl 2) S104-113
- 47 Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother. 1994; 38 624-627
- 48 San Gabriel P, Zhou J, Tabibi S, Chen T, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2004; 48 168-171
- 49 Toleman M A, Bennett P M, Bennett D M, Jones R N, Walsh T R. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis. 2007; 13 559-565
- 50 Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia . J Antimicrob Chemother. 2000; 45 363-365
- 51 Rolston K VI, Kontoyiannis D P, Yadegarynia D, Raad I I. Non-fermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis. 2005; 51 215-218
- 52 Lecso-Bornet M, Pierre J, Sarkis-Karam D, Lubera S, Bergogne-Berezin E. Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrob Agents Chemother. 1992; 36 669-671
- 53 Cheng A F, Li M K, Ling T K, French G L. Emergence of ofloxacin-resistant Citrobacter freundii and Pseudomonas maltophilia after ofloxacin therapy. J Antimicrob Chemother. 1987; 20 283-285
- 54 Insa R, Cercenado E, Goyanes M J, Morente A, Bouza E. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. . J Antimicrob Chemother. 2007; 59 583-585
- 55 Zelenitsky S A, Iacovides H, Ariano R E, Harding G KM. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia . Diagn Microbiol Infect Dis. 2005; 51 39-43
- 56 Poulos C D, Matsumura S O, Willey B M, Low D E, McGeer A. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia . Antimicrob Agents Chemother. 1995; 39 2220-2223
- 57 Krueger T S, Clark E A, Nix D E. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis. 2001; 41 71-78
- 58 Felegie T P, Yu V L, Rumans L W, Yee R B. Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination. Antimicrob Agents Chemother. 1979; 16 833-837
- 59 Nguyen M H, Muder R R. Xanthomonas maltophilia meningitis: case report and review of the literature. Clin Infect Dis. 1994; 19 325-326
- 60 Papadakis K A, Varivarian S E, Vassilaki M E, Anaissie E J. Stenotrophomonas maltophilia meningitis: report of two cases and review of the literature. J Neurosurg. 1997; 87 106-108
- 61 Girijaratnakumari T, Raja A, Ramani R, Antony B, Shivananda P G. Meningitis due to Xanthomonas maltophilia . J Postgrad Med. 1993; 39 153-155
- 62 Muder R R, Yu V L, Dummer J S, Vinson C, Lumish R M. Infections caused by Pseudomonas maltophilia: expanding clinical spectrum. Arch Intern Med. 1987; 147 1672-1674
- 63 Chen S, Stroh E M, Wald K, Jalkh A. Xanthomonas maltophilia endophthalmitis after implantation of sustained-release ganciclovir. Am J Ophthalmol. 1992; 114 772-773
- 64 Kaiser G M, Tso P C, Morris R, McCurdy D. Xanthomonas maltophilia endophthalmitis after cataract extraction. Am J Ophthalmol. 1997; 123 410-411
- 65 Karakurt A, Abdik O, Sengun A et al.. Stenotrophomonas maltophilia endophthalmitis after cataract extraction. Ocul Immunol Inflamm. 2006; 14 41-46
Robert R MuderM.D.
Infectious Disease Section 111E-U, VA Pittsburgh Healthcare System
University Drive C, Pittsburgh, PA 15240
Email: Robert.muder@va.gov